CVM - AMEX
CEL-SCI Corporation
$7.17
-6.5%CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
At a Glance
Live SnapshotCEL-SCI Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CEL-SCI Corporation Cash Flow Statement
CVM • AMEX
| CEL-SCI Corporation Cash Flow Statement | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | Sep 2007 | Sep 2006 | Sep 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-26.9M | -32.2M | -36.7M | -36.4M | -30.3M | -22.1M | -31.8M | -14.4M | -11.5M | -34.7M | -27.4M | -9.2M | -15.5M | -25.7M | 10.5M | -40.9M | -7.7M | -9.6M | -7.9M | -3M | |
4M | 4M | 3.8M | 2.2M | 2.2M | 633.5K | 650.1K | 632.9K | 150.2K | 206.8K | 231.8K | 364.1K | 533.5K | 531.3K | 516.1K | 417.2K | 464.2K | 1.4M | 275.3K | 190.4K | |
0.0 | 0.0 | 0.0 | 713.6K | 1.2M | 760.6K | 9.1M | -11M | -14M | 359K | -170.3K | -10.7M | 372K | 22.8M | -28.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
4.3M | 7.1M | 12.4M | 13.9M | 10.3M | 4.6M | 2.9M | 1.5M | 2.3M | 5.3M | 4.1M | 2.8M | 154.5K | 365K | 112.3K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.1M | 15.3K | 480.1K | 1.2M | 2.6M | 4.4M | 8.5M | 2.7M | 751.7K | 545.1K | 695K | 454.9K | 619K | -16.6M | 2.9M | 33.9M | 1.1M | 2.8M | -623.8K | -252.3K | |
-1.2M | -1.8M | 2.5M | -483.5K | -1.2M | -4.5M | -2.7M | 6.8M | -779.4K | 4.5M | -432.2K | 2.7M | 1.6M | -4M | 2.1M | 77.2K | -1.8M | 598.7K | -388.1K | 32.1K | |
-18.8M | -22.8M | -18.2M | -18.8M | -15.3M | -16.3M | -13.4M | -13.8M | -23.1M | -23.8M | -22.9M | -13.5M | -12.2M | -22.6M | -12.8M | -6.5M | -7.9M | -4.9M | -8.7M | -3.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-94.9K | -361.9K | -660.6K | -9M | -2.7M | -335.8K | -58.1K | -17K | -34.2K | -93.5K | -138.9K | -132.8K | -133.6K | -339.5K | -551.1K | -750.4K | -3.5M | -319.3K | -90.7K | -153.7K | |
(0.0) | (0.0) | (0.0) | -6.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -6M | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 6.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.8M | 0.0 | 0.0 | 0.0 | |
-13.2K | -10.4K | 6.1K | -6.2K | -39.0 | -158.0 | -57.0 | -6.0 | -2.0 | -20.0 | -34.0 | -30.0 | -78.0 | 21.4K | 47.2K | 1.1M | 1.2M | -7.1M | 0.0 | 0.0 | |
-108.1K | -372.3K | (5.5M) | -15.2M | -2.7M | -335.8K | -58.1K | -17K | -34.2K | -93.5K | -138.9K | -132.8K | -133.6K | -318.1K | -503.9K | (368.7K) | -2.5M | -7.4M | -90.7K | -153.7K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
23.7M | 6.6M | 0.0 | 47.6M | 14M | 0.0 | 11.8M | 10.5M | 21.4M | 21.1M | 28.4M | 9.8M | 14.3M | 3.9M | 0.0 | 32.2M | 1.1M | 15.6M | 1.9M | 549.8K | |
-1.8M | -1.6M | -600K | 534.2K | -800.2K | -5.1K | -6.3K | 2.7M | -1.1M | -8.5K | -8.1K | -6.9K | -5M | 0.0 | 0.0 | 149.8K | -845K | -407.5K | 13M | 367.3K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.4M | -297.6K | -38.4K | 6.4M | 11.8M | 14.8M | 9.6M | 0.0 | 0.0 | 0.0 | 3.1M | 0.0 | 2.7M | 679.6K | 6.3M | 6.6M | -23.8K | -10.2K | -15K | 0.0 | |
19.5M | 4.7M | -638.4K | 54.5M | 25M | 14.8M | 21.4M | 13.3M | 20.3M | 21.1M | 31.5M | 9.8M | 12M | 565.9K | 6.3M | 39M | 183.2K | 15.2M | 14.9M | 917.1K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
592.4K | -18.5M | -13.4M | 20.6M | 7.1M | -1.9M | 7.9M | -548.6K | -2.8M | -2.8M | 8.5M | -3.9M | -319.6K | -22.3M | -7M | 32.9M | -10.3M | 2.9M | 6.1M | -2.3M | |
4.1M | 22.7M | 36.1M | 15.5M | 8.4M | 10.3M | 2.4M | 2.9M | 5.7M | 8.5M | 41.6K | 3.9M | 4.3M | 26.6M | 33.6M | 711.3K | 11M | 8.1M | 2M | 4.3M | |
4.7M | 4.1M | 22.7M | 36.1M | 15.5M | 8.4M | 10.3M | 2.4M | 2.9M | 5.7M | 8.5M | 41.6K | 3.9M | 4.3M | 26.6M | 33.6M | 711.3K | 11M | 8.1M | 2M | |
-18.9M | -23.2M | -18.9M | -27.8M | -18M | -16.7M | -13.4M | -13.8M | -23.1M | -23.9M | -23.1M | -13.7M | -12.3M | -22.9M | -13.4M | -7.3M | -11.4M | -5.2M | -8.8M | -3.2M |
SEC Filings
CVM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | November 24, 2025 | November 18, 2025 | 2025 | |
S-3 S-3 N/A | November 07, 2025 | November 07, 2025 | ||
8-K 8-K 2025 N/A | November 05, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 29, 2025 | August 27, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 25, 2025 | August 22, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | August 05, 2025 | August 05, 2025 | ||
8-K 8-K 2025 N/A | July 14, 2025 | July 11, 2025 | 2025 | |
S-3 S-3 N/A | July 03, 2025 | July 03, 2025 | ||
8-K 8-K 2025 N/A | May 23, 2025 | May 21, 2025 | 2025 |
Related Guides
Continue your CVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.